| Literature DB >> 34053578 |
Katharina Dendl1, Joel Schlittenhardt1, Fabian Staudinger1, Clemens Kratochwil1, Anette Altmann2, Uwe Haberkorn2, Frederik L Giesel3.
Abstract
Fibroblast activation protein inhibitor emerges as a novel and highly promising agent for diagnostic and possibly theranostic application in various malignant and non-malignant diseases. FAPI impresses with its selective expression in several pathologies, ligand induced internalization, and presence in a large variety of malignancies. Current studies indicate that FAPI is equal or even superior to the current standard oncological tracer fluorodeoxyglucose in several oncological diseases. It seems to present lower background activity, stronger uptake in tumorous lesions and thus sharper contrasts. For improved comprehension of fibroblast activation, protein expression and clinicopathologic conditions, further studies are of essence.Entities:
Keywords: Cancer-associated fibroblasts; FAP; FAPI PET/CT; Fibroblast activation protein; Small molecule inhibitors
Year: 2021 PMID: 34053578 DOI: 10.1016/j.cpet.2021.03.012
Source DB: PubMed Journal: PET Clin ISSN: 1556-8598